Breaking News

Bayer Drops Out in the Race for Schiff

November 20, 2012

According to published reports, Bayer AG has ceased its pursuit of Schiff Nutrition International Inc., ending speculation that the deal was poised to become the industry’s most expensive acquisition.

Late last month German drugmaker Bayer announced its intent to buy Schiff for $34 a share, or about $1.1 billion including net debt, according to Bloomberg. The situation grew interesting when Reckitt Benckiser Group Plc made a surprise offer of $42 a share, or about $1.4 billion.

In a filing with the U.S. Securities and Exchange Commission Bayer said that a competitive bidding process “would result in a price outside Bayer’s set financial criteria.”

Related Market Segments:

Related Nutraceuticals:

blog comments powered by Disqus
  • Fortifying Women’s Health

    Fortifying Women’s Health

    Lisa Olivo, Associate Editor||May 2, 2016
    From pregnancy to PMS to menopause and more, women are turning to natural products to protect and preserve their health.

  • Building On Transparent & Sustainable Foundations

    Building On Transparent & Sustainable Foundations

    Sean Moloughney, Editor||May 2, 2016
    Socially responsible products that are mindful of the environment appeal to a growing audience.

  • The Ins & Outs of Pectin

    The Ins & Outs of Pectin

    Simi Summer, PhD, Contributing Writer||May 2, 2016
    With novel sources and functions for multiple markets, pectin is a key ingredient to watch.